Nature of Funding: :
Equity - Venture
Use of Funding: :
Seed Funding
Sector: :
Biomedical
Amount: :
£150,000
Date of Investment :
June 2013
Location: :
Halton
Fund :
North West Fund for Biomedical
Summary
Founded in 2012 by Dr Sam Westgate and Keith Cutting, Perfectus Biomed Group developed into a leading Contract Research company with laboratories in the UK and North America providing standard and customised microbiological testing services.
In 2013, SPARK Impact Ltd who have operationally merged with River Capital, invested a six-figure amount into Perfectus Biomed Group who at the time had three full-time staff. By the date of exit, that number had increased significantly to 50 personal in full-time roles, following impressive growth.
Sectors in which Perfectus operated included wound care, medical devices, infectious diseases, disinfectants, industrial and oral care and dentistry, and throughout the global pandemic that was COVID-19, the business played a pivotal role in helping companies determine what products were safe to use during this time.
In 2020, the company strengthened when it acquired a US-based CRO serving complimentary sectors, establishing a Group that could provide a complete service to customers with US and European operations.
In 2022, having established a first-class reputation, the world-leading MedTech CRO, NAMSA, acquired Perfectus, adding it to its extensive suite of European-based laboratories in doing so. This exit saw SPARK Impact Ltd earn an impressive return on their initial investment.
Testimonial
‘Over a 10 year period SPARK Impact Ltd representatives consistently supported the team at Perfectus Biomed. They provided sound advice, follow on funding and guidance throughout the growth journey and throughout the exit period.’ The appointed representatives were great to work with and we learned a lot from them as we grew the company. Thank you for believing and investing in our team!
Dr Sam Westgate - Executive Director Perfectus Biomedical Group